| Old Articles: <Older 4931-4940 Newer> |
|---|
 |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play?   |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
The Motley Fool
June 24, 2008
Brian Lawler |
Barrier Taken Down Barrier Therapeutics announces that Stiefel Labs will buy them for $148 million. |
IEEE Spectrum
June 2008
Sandra Upson |
RFID Systems May Disrupt the Function of Medical Devices Researchers ask whether hospitals should adopt new guidelines for medical electronics' interoperability. |
The Motley Fool
June 23, 2008
Brian Lawler |
Wait a Little Longer, Ligand The FDA delays its review of GlaxoSmithKline and partner Ligand Pharmaceutical's blood-disorder drug Promacta. |
The Motley Fool
June 23, 2008
Brian Lawler |
Sanofi Goes East to Find Growth Sanofi-Aventis announces that it has outbid a rival for Czech generic-drug maker Zentiva. |
The Motley Fool
June 23, 2008
Brian Orelli |
FDA Sets a Higher Standard for Merck Merck finally comes clean on what the FDA wants before the drug formally known as Cordaptive (MK-0524A) can be approved. From the looks of it, it's going to be a long wait for Merck. |
National Defense
July 2008
Alan L. Gropman |
Out-of-Control Healthcare Spending Straining Budget Controlling costs and expanding access are perhaps the greatest challenges facing the U.S. healthcare industry in the first quarter of the 21st century. |
The Motley Fool
June 20, 2008
Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
The Motley Fool
June 19, 2008
Brian Lawler |
Pfizer's Small Lipitor Win Pfizer and the most prolific challenger of its Lipitor patents, Indian generic-drug manufacturer Ranbaxy, settle the vast majority of their litigation. |
| <Older 4931-4940 Newer> Return to current articles. |
